about
[Myelodysplastic syndrome mimicking idiopathic thrombocytopenic purpura].Gemcitabine and Infusional 5-Fluorouracil in Advanced Pancreatic Cancer: A Clinical Benefit Response-Oriented Phase II Study.Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry.Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea.Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter studyEffect of anemia correction on left ventricular structure and filling pressure in anemic patients without overt heart diseaseA prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myelomaSubmicroscopic deletions of immunoglobulin heavy chain gene (IGH) in precursor B lymphoblastic leukemia with IGH rearrangements.Transplant physicians' perceptions of cord blood transplantation in Korea: a questionnaire surveyTreatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea.Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic SyndromeEfficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study.Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation.A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndromeA proposal for improvement in the utilization rate of banked cord bloodAcute fibrinous and organizing pneumonia following hematopoietic stem cell transplantation.Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.A case of Wernicke's encephalopathy following fluorouracil-based chemotherapy.Gefitinib trial in a fanconi's anemia patient with multiple squamous cell carcinomas and hepatocellular carcinoma.Success rate and risk factors for failure of empirical antifungal therapy with itraconazole in patients with hematological malignancies: a multicenter, prospective, open-label, observational study in KoreaPrevention of venous thromboembolism, 2nd edition: Korean Society of Thrombosis and Hemostasis Evidence-based Clinical Practice Guidelines.Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide.Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.Incidence of venous thromboembolism following major surgery in Korea: from the Health Insurance Review and Assessment Service database.Comprehensive Evaluation of the Revised International Staging System in Multiple Myeloma Patients Treated with Novel Agents as a Primary Therapy.Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome.Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma.Genome-wide genotype-based risk model for survival in acute myeloid leukaemia patients with normal karyotype.Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia.Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia.Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients.Multicenter Retrospective Analysis of Clinical Characteristics, Treatment Patterns and Outcomes in Very Elderly Patients with Diffuse Large B-cell Lymphoma: The Korean Cancer Study Group LY16-01.Novel deletion mutation of HLA-B*40:02 gene in acquired aplastic anemia.Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.Adherent cells generated during long-term culture of human umbilical cord blood CD34+ cells have characteristics of endothelial cells and beneficial effect on cord blood ex vivo expansion.The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea.
P50
Q33389444-8E6A0923-E3B3-4C33-8ECE-FC95A8062105Q33428501-DB6D6032-5354-48EE-B9B0-5D170ED52469Q33514792-2E0908FD-3FBC-4041-A0E0-22AAF3163A55Q33786873-C0295C8C-53C6-4CE6-8004-DE5DEA6E23D2Q33891364-21B4F989-E82E-42DA-9D3E-F6928D376009Q33912879-1449C957-A156-4FA5-8622-2083C80889BBQ33914056-1C1E43CC-D845-4241-9831-2D07B8AC0787Q34749600-57283976-40FF-480E-8F58-0394FDCF8451Q34779382-36873EA9-E05D-4A3C-9942-76B3C72EC82DQ35429833-86C3A616-C523-4F4F-8004-46C15E58F1B3Q36081225-74F61DD8-ED96-452F-AEB9-C8B10B316904Q36185741-6050AD0F-E873-4B47-A699-FBAAC342AFDFQ36456366-7AD08203-B343-4B75-BDA5-46F00B236CB5Q36536365-4F444123-7BAD-4895-B796-31AA2E9E364FQ36689145-3960E945-46D3-409A-9061-A39AC06CF5D2Q36761816-A974E323-491E-48E8-87D2-78A8ED61A996Q37233087-B1D5EB97-6D46-458A-893C-8C55ECB3E60BQ37237918-DAE70FEB-F5A5-40C7-A037-F0801A2F2D94Q37284680-E6CFA3E4-22B3-4534-89E0-A265E86B0082Q37449269-A0ACA05E-22A2-4856-A9FF-BB5E7E7D33D3Q37473671-237E0C67-5529-4F3C-95D2-6CAE4C85BC1BQ37583019-18DDC40F-9059-429A-92D2-77577192F308Q37586204-2084ABDC-B0A0-441B-98A1-5B47766DC24FQ37687767-06950C25-C0EE-4FE4-BE65-BF9E15300706Q38212499-CA41FEF2-82DB-40E4-A205-E3E28F4B436AQ38399487-BBB8E840-C496-456C-9555-3DD5C531B1BEQ38425292-D4A40A74-7CE8-46DA-9202-6CA428C59097Q38426101-3C98230D-370B-4F73-B18E-63A82CD25771Q38445540-948F5EE3-4468-483C-B976-E3CBA727C660Q38446990-634EFBEC-D3E3-4C0A-AF35-D0EAB7D2D9CBQ38451661-6C2C3188-DA3C-4160-94E3-22E74D032EDAQ38455680-ECCCA8A7-9586-4F6F-B67F-EE9E3F7E9F41Q38459577-A393A207-A90D-4B46-9AC4-52A2AA2B293CQ38460343-1713CBEB-F3F9-4E2B-B4DF-E8613122DD46Q38482881-049FCD0E-478C-4F12-AB1F-BC1B0FC1A409Q38731955-5F4F5745-6744-4E33-ACD0-31D3F7A3F62BQ39062911-016CA1F9-DF51-4A60-BFDB-2716DB80F9B0Q40345967-C5AEAE16-D812-4C44-9511-3F305089C726Q40600615-44AD5DA5-313D-428D-BA7D-424BCFAF4CCBQ40813914-3FD2B040-B4E3-42EA-B8A4-76C7A124A59E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Yeung-Chul Mun
@ast
Yeung-Chul Mun
@en
Yeung-Chul Mun
@es
Yeung-Chul Mun
@nl
Yeung-Chul Mun
@sl
type
label
Yeung-Chul Mun
@ast
Yeung-Chul Mun
@en
Yeung-Chul Mun
@es
Yeung-Chul Mun
@nl
Yeung-Chul Mun
@sl
prefLabel
Yeung-Chul Mun
@ast
Yeung-Chul Mun
@en
Yeung-Chul Mun
@es
Yeung-Chul Mun
@nl
Yeung-Chul Mun
@sl
P106
P1153
7003363716
P31
P496
0000-0002-1882-3983